Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Breast Cancer Antibodies Market Opportunity: > USD 15 Billion
- Breast Cancer Antibodies Clinical Trials Insight: > 150 Drugs In Trials
- Breast Cancer Biomarkers Sourced During Clinical Trials
- Breast Cancer Biomarkers Insight By Antibodies Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Antibody
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
A biomarker refers to a biomolecule or gene used to precisely evaluate pharmacologic, pathogenic, and biological procedures in the body. They serve as an early warning in our bodies. Biomarkers are playing an increasingly important role in the detection and management of patients with several different cancer types, including breast cancer. In the case of breast cancer, the biomarkers are increasingly useful in the identification of individuals at increased risk of developing the malignancy within high-risk families, determining prognosis at the time of initial diagnosis, identifying the most appropriate systemic therapy, postoperative surveillance, and monitoring therapy in advanced disease
Although mammograms are a useful tool for catching breast cancer early, they aren’t typically recommended for low-risk women under 40. To mitigate this limitation, recent research study has identified a potential biomarker in breast milk. These biomarkers are also detectable in blood serum; therefore early screening could potentially be done in women of any age using blood or breast milk. The newly identified biomarkers are for a specific type of cancer called invasive ductal carcinoma, which is one of the most common types of breast cancers. However, researchers believed that their approach could be used to identify biomarkers for other types of breast cancer, too.
Further, conventional diagnostic procedures for breast cancer were focused on delivering accurate and consistent results; however, the biomarkers market demand includes early diagnosis with consistent and accurate outcomes. The utilization of biomarkers in the designing of diagnostic tests has gained interest from large number of pharmaceutical companies. Recently, Amoy Diagnostics (AmoyDx) and AstraZeneca have signed a master collaboration agreement for multiple companion diagnostics programmes in China, Japan, and the European Union. Through the collaboration, the companies will co-develop and commercialize AmoyDx assays that may cover any indication or biomarker type for companion diagnostic (CDx) use with AstraZeneca medicines across the world. It also includes a CDx development which will be used for detecting breast cancer patients, in the EU, with BRCA gene mutations for Lynparza (olaparib) monotherapy.
As per our report findings, the global breast cancer biomarker market is expected to surpass US$ 15 Billion by 2028. It is anticipated that the status of breast cancer as one of the world’s most prevalent cancers is a major driver of the global market. Key market players concentrated their efforts on research and development in order to develop new and reliable biomarkers for superior diagnosis and treatment. Collaborations of various key market players with research institutes with the goal of developing novel breast cancer biomarkers for personalized medicine are also expected to drive market growth during the forecast period. The major companies mentioned in the report are Amgen, Roche, Pfizer, Gilead Sciences, GlaxoSmthKline, and others. Additionally, increasing awareness about breast cancer and its early diagnosis will also have a positive impact on the growth of market during the forecast period.
Our report provides in-depth analysis on the currently available biomarker across various stages of clinical trial. This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. Our services intend to provide a competitive edge to stake holders by uncovering the future growth patterns of this industry through a deep study of past records and latest global developments. The report have been drafted in such a way that companies can easily comprehend the market trends and future prospects to form business strategies that will turn in strong profits in the upcoming years. Additionally, our reports also provide information to various challenges along with measures which will impact the growth of market during the forecast period.